Clinical Trial Update: Safety and Efficacy of Combination HDI and Anti-CTLA4 for Recurrent Inoperable Stage III or Stage IV Melanoma [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluated the safety and efficacy of combining High-Dose Interferon alfa-2b with an anti-CTLA-4 antibody in patients with recurrent inoperable s…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma

Drugs mentioned

• Anti-CTLA-4 antibody
• High-Dose Interferon alfa-2b (interferon alfa-2b)

Snippet

Sponsor: Ahmad Tarhini | Conditions: Melanoma | Phase 2 | Status: COMPLETED | Results posted: 2016-10-17